Open Access
Open access
volume 15 issue 2 pages 221

Recent Advances in the Biological Activity of s-Triazine Core Compounds

Publication typeJournal Article
Publication date2022-02-12
scimago Q1
wos Q1
SJR1.019
CiteScore7.7
Impact factor4.8
ISSN14248247
PubMed ID:  35215333
Drug Discovery
Pharmaceutical Science
Molecular Medicine
Abstract

An effective strategy for successful chemotherapy relies on creating compounds with high selectivity against cancer cells compared to normal cells and relatively low cytotoxicity. One such approach is the discovery of critical points in cancer cells, i.e., where specific enzymes that are potential therapeutic targets are generated. Triazine is a six-membered heterocyclic ring compound with three nitrogen replacing carbon-hydrogen units in the benzene ring structure. The subject of this review is the symmetrical 1,3,5-triazine, known as s-triazine. 1,3,5-triazine is one of the oldest heterocyclic compounds available. Because of its low cost and high availability, it has attracted researcher attention for novel synthesis. s-Triazine has a weak base, it has much weaker resonance energy than benzene, therefore, nucleophilic substitution is preferred to electrophilic substitution. Heterocyclic bearing a symmetrical s-triazine core represents an interesting class of compounds possessing a wide spectrum of biological properties such as anti-cancer, antiviral, fungicidal, insecticidal, bactericidal, herbicidal and antimicrobial, antimalarial agents. They also have applications as dyes, lubricants, and analytical reagents. Hence, the group of 1,3,5-triazine derivatives has developed over the years. Triazine is not only the core amongst them, but is also a factor increasing the kinetic potential of the entire derivatives. Modifying the structure and introducing new substituents makes it possible to obtain compounds with broad inhibitory activity on processes such as proliferation. In some cases, s-triazine derivatives induce cell apoptosis. In this review we will present currently investigated 1,3,5-triazine derivatives with anti-cancer activities, with particular emphasis on their inhibition of enzymes involved in the process of tumorigenesis.

Found 
Found 

Top-30

Journals

1
2
3
4
Journal of Molecular Structure
4 publications, 8.51%
Russian Journal of General Chemistry
3 publications, 6.38%
RSC Advances
3 publications, 6.38%
Crystals
2 publications, 4.26%
Structural Chemistry
2 publications, 4.26%
Archiv der Pharmazie
2 publications, 4.26%
Dalton Transactions
2 publications, 4.26%
New Journal of Chemistry
2 publications, 4.26%
Журнал Общей Химии
2 publications, 4.26%
Materials Advances
2 publications, 4.26%
Coordination Chemistry Reviews
1 publication, 2.13%
Inorganics
1 publication, 2.13%
Molecular Crystals and Liquid Crystals
1 publication, 2.13%
Environmental Research
1 publication, 2.13%
Pharmaceuticals
1 publication, 2.13%
Pharmacology and Therapeutics
1 publication, 2.13%
Heliyon
1 publication, 2.13%
Bioorganic Chemistry
1 publication, 2.13%
Results in Chemistry
1 publication, 2.13%
Chemistry and Biodiversity
1 publication, 2.13%
Chemistry Letters
1 publication, 2.13%
Russian Journal of Bioorganic Chemistry
1 publication, 2.13%
European Journal of Organic Chemistry
1 publication, 2.13%
Mendeleev Communications
1 publication, 2.13%
Mini-Reviews in Medicinal Chemistry
1 publication, 2.13%
Polymers
1 publication, 2.13%
Analytical Chemistry Letters
1 publication, 2.13%
Molecules
1 publication, 2.13%
ACS Applied Polymer Materials
1 publication, 2.13%
1
2
3
4

Publishers

2
4
6
8
10
12
Elsevier
11 publications, 23.4%
Royal Society of Chemistry (RSC)
9 publications, 19.15%
MDPI
6 publications, 12.77%
Pleiades Publishing
6 publications, 12.77%
Wiley
4 publications, 8.51%
Springer Nature
2 publications, 4.26%
Taylor & Francis
2 publications, 4.26%
Oxford University Press
1 publication, 2.13%
OOO Zhurnal "Mendeleevskie Soobshcheniya"
1 publication, 2.13%
Bentham Science Publishers Ltd.
1 publication, 2.13%
American Chemical Society (ACS)
1 publication, 2.13%
Scientific Scholar
1 publication, 2.13%
FSBEI HE I.P. Pavlov SPbSMU MOH Russia
1 publication, 2.13%
2
4
6
8
10
12
  • We do not take into account publications without a DOI.
  • Statistics recalculated weekly.

Are you a researcher?

Create a profile to get free access to personal recommendations for colleagues and new articles.
Metrics
47
Share
Cite this
GOST |
Cite this
GOST Copy
Maliszewski D., Drozdowska D. Recent Advances in the Biological Activity of s-Triazine Core Compounds // Pharmaceuticals. 2022. Vol. 15. No. 2. p. 221.
GOST all authors (up to 50) Copy
Maliszewski D., Drozdowska D. Recent Advances in the Biological Activity of s-Triazine Core Compounds // Pharmaceuticals. 2022. Vol. 15. No. 2. p. 221.
RIS |
Cite this
RIS Copy
TY - JOUR
DO - 10.3390/ph15020221
UR - https://doi.org/10.3390/ph15020221
TI - Recent Advances in the Biological Activity of s-Triazine Core Compounds
T2 - Pharmaceuticals
AU - Maliszewski, Dawid
AU - Drozdowska, Danuta
PY - 2022
DA - 2022/02/12
PB - MDPI
SP - 221
IS - 2
VL - 15
PMID - 35215333
SN - 1424-8247
ER -
BibTex |
Cite this
BibTex (up to 50 authors) Copy
@article{2022_Maliszewski,
author = {Dawid Maliszewski and Danuta Drozdowska},
title = {Recent Advances in the Biological Activity of s-Triazine Core Compounds},
journal = {Pharmaceuticals},
year = {2022},
volume = {15},
publisher = {MDPI},
month = {feb},
url = {https://doi.org/10.3390/ph15020221},
number = {2},
pages = {221},
doi = {10.3390/ph15020221}
}
MLA
Cite this
MLA Copy
Maliszewski, Dawid, and Danuta Drozdowska. “Recent Advances in the Biological Activity of s-Triazine Core Compounds.” Pharmaceuticals, vol. 15, no. 2, Feb. 2022, p. 221. https://doi.org/10.3390/ph15020221.